A new treatment option for patients with moderate-to-severe Atopic Dermatitis: Targeting the IL-31/IL-31R signaling pathway

Amphitheatre A

Date: Friday 20 September 2019, 08.30-09.30
Room: Amphitheatre A

Chair: Alain Taïeb (Bordeaux, France)

Symposium summary

Chair Professor Alain Taïeb will be joined by Professors Marjolein de Bruin Weller, Bernhard Homey, and Jean-David Bouaziz for this Galderma-sponsored educational symposium exploring the role of  IL-31/IL-31R in the pathogenesis of atopic dermatitis, and the therapeutic potential of blocking this signaling pathway. Many patients with moderate-to-severe atopic dermatitis have a high disease burden, and continue to experience symptoms and reduced quality of life despite treatment. Therefore, there remains an unmet need for new treatment options for patients whose disease is not adequately controlled by currently available therapies. The IL-31/IL-31R signaling pathway represents a promising novel therapeutic target for these patients.


08.30-08.32 Welcome and introduction
Alain Taïeb (Bordeaux, France)

08.32-08.50 Are patient needs being met?
Marjolein de Bruin-Weller (Utrecht, The Netherlands)

08.50-09.08 IL-31/IL-31R: Inflammation, nerves, and the skin barrier – implications for pathophysiology of atopic dermatitis
Bernhard Homey (Düsseldorf, Germany)

09.08-09.26 Clinical perspectives in moderate-to-severe atopic dermatitis: Targeting IL-31/IL-31R
Jean-David Bouaziz (Paris, France)

09.26-09.30 Summary and close
Alain Taïeb (Bordeaux, France)